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Although initially developed to redo,, the risk of bleeding,
second-generation (clot-selective) thrombolytic agents have been
found to induce more pranpt and frequent retanatiraann than do
nenselective, first-generation v6 nts. To determine whether they
do ss in part by preserving clot-associated plasminogen, human
whole blond clots formed in Chandler tubes were studied. Addition
OF sOpeapharvucdogic concentrations of recombinant tfmrestlpe
plasmlnagen activator (N-PA) to the media haddng moron c acs led
to a paradoode impairment of clot tysi, and a eeneenetaet camen-
hattan-dependent depletion ofout-aaadated ploonta gee (W aetern
blot analysis). In contrast, suppimneeraden of The plasma with
plasminogen 40,27 mgJmll led to significant coesavatien of bath
plasma and clm-associated plasminogen (p
-
&Od, n = 41, and
prevented the diminution of clot lysis (p -
0
.05
; n = 4)-
Fibrinogen degradation products did not ntruism fee the alenu-
ation of lysls with the highest concentrations of rt-PA
.
In cenreulra-
liass equivalent to those that were induced by the highest cmnetaen-
Agents used to induce fibrinolysis clinically differ with respect
to their relative clot or fibrin selectivity
. Second-generation
agents such as recombinant tissue-type plasttvnog
n activator
(rot-PA) (alteplase or Artivase) and prourokinase (Saruplase)
are more clot selective than are first-generation agents such as
streptokinase (Streplase), anisoylated plasminogen activator
complexes (APSAC) (anistreplase or Enlinase) and urokinase
(1-3) .
Second-generatirm agents were developed initially to
reduce the risk of bleeding
. However, they have been found to
induce recaralization of cormmry arteries more promptly and
more frequently than do firsl-generation agents
(4-6) . We
hypothesized that their enhanced cdieacy is a reflection, in
part, of a paradoxic diminution of clot lysis seen when plas-
minemia and concomitant depletion of fibrinogen and plas-
minogen from blood occur with first-generation fihrinelytic
agents-phenomena encountered regularly with their
adminis-
tration (7,8)
.
We postulated that depletion of plasminogen
from plasma would result in leaching of clot-bound plasmino-
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lions of rt-PA evaluated, fibrinogen degradation products
potentiated rather than inhibited lyss (p = 0,05 . a = 4), probably by
stimulating el-PA activity dirsMy
. When
1-formed
cbns
wtxe
incubated with plasminoern-depleted plasma plus 1fflill nghM
rot-PA, thep ogencontenttoresidualclotdectined(9
.36±0.46
versus 12 .39 r 0.69 ag/urn dot fount in rrondeptesed plasma ; p
0.05; n = 6) . Furthermore, dot lysts wag afterwated s mphhrY-
Thus, clot lysis induced by adivat:on of piesmittagen is depen-
dent on clot-associated plasminogen, wblet, in turn depends an the
concentrationof plasminogen in plain, ISepletton of irdh is likely
to
contribute to the loner fregnenay and rapidity of coronary
recanalirattcn ind rd with nnrst
.4-reteenre rampnred with se-
tective sih'neiytk agents beusase of the depletiioa or Breton
plasminogen and the plasminogen best they characteristically
Induce.
(J An Coif Cardiof J992;l9:IQ85-90)
Zen into the plasminogen-depleted fluid phase 4" plasanogen
steal' -) (9) .
Although changes in plasma plasnnogen accompanying
fibrinolysis are consistent with this hypothesis, quantitative
relations among induced changes in concentrations of
plasma plasminogen, clot-associated plasminogen and rate
and extent of clot lysis have not yet been characterized . The
present study was performed with a second-generation agent
to define these relations and to determine whether plasmi-
nogen steal is likely to
contribute m the differential effects of
first- compared with second-generation fibrinolytic agents on
the rapidity and frequency of coronary recanalization .
Methods
Experiments were performed in vitro with human recom-
binant deoxyribonucleic acid (DNA) tissue-type plasmirm-
gen activator (rot-PA) produced
in Chinese hamster ovary
cells (Genentech). Enzyme-linked immunosarbent assay
(ELISA) reagents were obtained from American Divgnostica
for assay of rt-PA performed as previously described
(10) .
High molecular weight protein standards for use with sodium
dodecyl-sulfate polyacrylamide gel (SDS-PAGE) electro-
phoresis and Western blotting were obtained from BioRad
.
Induction melon in vitro . tnforated written consent was
obtained from all subjects for blood sampling, and the study
was conducted in accordance with the Ethical Guidelines of
0735-1037192155.011
1096
	
TORR FT AL
PLASMINMEN STEM
The Human Studies Committee of the Washington University
School of Medicine .
Human blood clots were formed in Chandler tubes as
previously described 19,111 after oJlcct ion of r
unple s from the
anteonbital vein in normal volunteers with a 19-gauge needle
and a polypropylene syringe . Rlcod was transferred quickly to
a 27-em long Tygoa tube (internal diameter = 0.125 in,
[0.318 em[ ; outer diame s = o PAR in-10 .475
eml, I ml blood
per tube ; Fisher Scientific) that a
•ass connected at both ends
with a I cm
collarof
Tyge n tubing (internal diameler0 .Ifh in .
(0.475 cm)
; outer diameter 0.312 in. (0 .792 cm). After addition
of 3 .5 pg of fihrinogen
)
fiabi V itrum t, the tubes were related on
strobe rotator (Scientific Equipment Company) far(A ml n at an
angle of00' ar 30 rpm, simulating blood flows of approximately
30 ntb'i in. Clot formation was cc •m plete within I h as dmu-
treated previously (121.
Eflecls of depletion of plasminogen from [be fluid phase.
Venous blood was drown into sodium citrate (3
.891 and
centrifuged at t,350 x g for 10 min to obtain plasma from
normal volunteers who had not taken any medication including
aspirin and noosterevf anti-inflammamry agents for at least 3
weeks
. Coal anti-human plasminogen (Sigma F-5278) was
added to a final, oncemration of 20 mglml . An equal volume of
plasma was placed in another tube that contained no antibody.
After vigorous shaking of the samples in both tubes overnight
on a rotator at 4°C, prot°in G was added 11 :10 volume/volumel
to precipitate the plasminogen
. After further incubation and
rotation for 2 h at room temperature . the plasma was centri-
fuged at 1,100 x g for 19 min at 4`C. The supernatant fraction
was removed and assayed for residual plasminogen with a
chromogenic substrate (S-2254 and reagents from Kabi Vit-
rum
. The concentration of plasminogen in the depleted plasma
that had been trend with antibody was only 5f of that in
autolagous control plasma (n = 2) .
Clots that had been formed in (.'haodtor tubes were
transferred into tubes with either normal or plasminogen-
depleted plasma and incubated while rotating at 37'C for an
additional 60
min,
Subsequently, the cuncenlrution of plas-
min that had been generated io the fluid phase of normal or
plasminogen-depleted plasma bathing the clots was assayed
with another kinetic chromogenic substrate assay (Spec-
trozymc-PL ., American Diagnostica) .
Effects on clot lysis
of sapplemeutatiou of blond with
fihrinogendegradation products, To determine whether pen .
ecation of
high concentrations of fibrinogen degradation
products accompanying generation of plasmin may account
for the decreased rate and extent of clot lysis attributed to
plasminogen steal by competing with the binding of activator
to fibrin . vre pet formed experiments wtdr the addition of high
concentrations of
fibrinogen degradation products (50 pg)ml
of whole blood) . Fibrinogen Degradation products were
prepared by incubating plasmin lKabi Vitrum) with exoge-
nous frbt sogen (Kabi Vitrum) for IS min at 37'C and were
subsequently assayed by the staphylococcal clumping method
(Sigma Diagnostic Kit No . 850)
. Clots were allowed to mature
for I h before small volumes of a concentrated solution of
jACC''ol . 19. No. 5
Apd
fibrinogen degradation products oe saline solution were added
to the whole blood . After a 5-min incobatios with either the
fihrinngen degradation products a saline solution . selected
concentrations of rt-PA 11 .1130 to MAO ng'ml) were added in
the medium . The extent of
clot pets was assayed gravimetri-
rally on the hnsis of the percent reduction of dry weight
or
u Bated clots compared with the weight of untreated clots from
the same blood samples .
Extraction of chtt .msocimed plasminogen. [ach clot was
removed from the Chandler tube at the end of the experi-
ment and washed extensively over a polyethylene mesh filter
(Spectrum Medical Industry . No . 1463561 with saline sulu-
tion containing Tween-201095% volumelvolume)- hfler the
wet weight of clots had been measured, the clots were
he mogeri zed manually at 4't7 in a Dual
glass homogcni zer to
IOU µ1 of sodium chloride (NaCI} . 29 :uhf :. T s, 10 mM;
ethylenediaminetetroacetic acid IEDTAI. I mM;
epsilon-
amino caprice acid (c-ACA) . 15 molt Triton X-IUD, 0.5%.
and aprotinin . 400 KIU3ml at pH R . fd-Phertylalonyl-t.
prolyl-L-arginine chloromethyl ketone (PPACK) (Pmclraaed
from Calbioehcm) was added to the homogenate to yield a
drool concentration of 2 geM. The homngemzer was rinsed
oath 50
Jul of the same buffer, the rinse was combined with
the homogenate, and both were centrifuged in cemricon-3
microconcentrator tubes (Amicon) . The microconcentrators
were pesoaked for 24 h with 2 ml of phosphate-buffered
saline solution containing bovine serum albumin, 5 mgim] .
and bovine gamma globulin, 2 .5 ngiml . Before addition of the
homogenate
. the phosphate-buffered saline solution was
discarded and the microconcemrator tube was centrifuged
for 2 min at 1,000 x g at 4`C in a Sorvall RC-5 centrifuge .
Homogenates were centrifuged in the microconcentrator
tubes at 5,1100 x g at 4`C for I h . The filtrate was discarded .
and solvent of the retentate was supplemented three times
with 9 volumes of sodium phrssphnte buffer containing 400
KIU/ml aprotonin at pH 8 per 1 volume of retentate . which
was centrifuged at 5 .1100 x g at 4'C until the volume of the
retentate was approximately 40 µi (usually overnight). The
final retentate was centrifuged at 1,)0 x p for 2 min- The
ftltcr was trashed with 20 µl of the same buffer, and the 60-µI
final combined volume was stored at -71r°C until Western
blot analysis was performed to quantify plasminoger . that
had been extracted from (he clots
.
Assn) ofactiratabfeplasminogenandofpiurmin . Concen-
trations of nclivatab[c plasminren were determined by
incubating 50µd of plasma with 50 pd of 0
.166 df hydrogen
chloride 1}lCl) at room temperature for 15 min, neutralizing
the sample with 50 asl of 0 .166 M sodium hydroxide to
inactivate inhibitors, diluting with 1
.0 ml of 50 mM Iris-HCI,
12 mM NaCl . pH 7 .4
. adding streptokinase (1,000 U in
IN ,ai water. Sigma) to 200 pI of diluted sampic in a
spectrophotometer cuvette at 37 7C, adding 700 µl of buffer
containing the chrumogenic substrate, .S-2251 (final concen-
tration
= 0.8 mM l
. and measuring A,as as a function of time.
Standard curves were obtained with several dilmions of
pooled (n = 10 donorsl . citraled, normal human plasma .
[ACC Vul. IS . Nu . 5
April
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Values were expressed as a percent of vanes in untreated
control samples .
Fm asnan
of
otr un m_ a second chromogeaic suhstr'„re .
Spectrozyme PL l ADI[ . was used . Samples were collected
into 2-ml EDTA-vacmainer tubes (Becton Dickinson) con-
taining a find concentration of 2 pM of PPACK and were
assayed immediately . Standard curves were obtained with
plasmin 15igmal by nmaSni ing A,,,, as a function of time .
Standard curves obtained with and without PPACK did not
differ, indicating that PPACK had no effect on measurable
plasmin activity under the conditions employed .
A
Quantification of plasminogen . For quantitation of clot-
bound plasminogen, Western blotting was performed . After
clots had been homogenized and extracted, 7 .57 sudhim
dodecyl sulfate polyaerylamide gel electrophoresis tSDS-
PAGE) was performed under nonrcducing conditions with
samples and standards (3 .11- to 190-pglml human glu-
;tlasminugen. ADI No. 419) in slab gels according to the
method of Laemmli (131 . Sequential proteins in the gel
were transferred electrostatien!ly in 0 .45 Pro nitrocellulose
ISchleicher and Schuell) at 4°C W X) V . 11
.3 A for 60 11110). The
gel and nitrocellulose sandwich was removed and blocked
overnight with 50 ml of buffer containing Tris-HCI . 50
Infl :
NaCl. 150 mM : and 2% bovine serum albumin (Buffer A) . pH
7 .5, at 4°C with constant agitation
. Iodine-025 goat antimouse
immunoglohulin G 11 .3 x 10° cpm(mll was prepared with goat
aminuatse immunoglohulin G TSigma. M-80901 and carrier-free
sodium iodide-125 (Amersham) by The chloramine-T method.
monoclonalantrk.odyagainst human gln-ptasminn~n, w hich
cross reacts with plasmin only minimally 1141 was used to
detect plasminogen [ADI no . 3641) . The nitrmellulose was
incubated for 60 min with 100 »gtml of the antibody with
constant agitation at 32'C and washed four times at mom
temperature (10 minlwashi with 20 ml of buffer containing
Tris-HCI, 30 mM
; NaCI . 150
mM: 0 .25{ of sodium dudes
sulfate, 0.5% bovine scram albumin and 0 .5cle of Triton X-`Alt
(Buffer B) : it was then washed once with 20 nil of Buffer A . The
nitrocellulose was then incubated for 60 min with 20 ml of 1 .125
goat antimouse immunoglabulin G 11 .3
Ia 10r'
cpmtmf . specific
activity = 0.26 x toe cpm'pgl at 37C with agitation The
nitrocellulose was washed again fourtimes with 20 ml of Buffer
B for 10 min and once more with 20 ml of distilled water with
agitation for 10 min
. Autoradingrams were developed with
Kodak Diagnostic Filters IX-OMAT . XAR-51 and Cronex
intensifier screens at -70"C for I81o 24 h . Areas corresponding
to labeled plasminogen bands were cut out, and radioactivity
was quantified by gamma counting . The recovery of plasmin
gen as judged from results with added standards was 939r In
4).
Effects on clot lysis of supplementation of medium bathing
clots with plasminogen . Ta determine whether - supplementa-
tion with plasminogen of medium bathing clots attenuated
effects attributed to plasminogen steal li
n t
.- the paradoxi-
cally decreased clot lysis observed with curtained . high
concentrations of rt-PA(. clots were formed by addition of
3 .5l g of fibrinogen to I ml of whpte bleed and totaled for I h
TORR ET AL .
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at 37° C. Either rt-PA [final concentration 4 .000 nglml) or
pirosphaie-hufiered saline solution was added in equal vot-
eme- an' the tubes were rotated at 37°C for an additional
30 min . Either human glu-plasminogen (final concentration
0 . 27
mgml) or phosphate-huffered saline solution in equal
volume was added alter 6 min and again after 15 min of
intubation . When incubation was complete . the fibrin-rich
	 : ;f the c;o,
-s os
mmoved (15) and placed taro a Uvai
hotuogcntzer in 100 Al rINaCI . 20 ; 14; Ins. IO .aM:
I mM
: E-ACA . 0 mM ; 0. 5% Triton X-Itkl and aprotinin,
400 K
IUImt. at pH 8. An additional 50 pl of buffer was used to
rinse the sides of the homogenizes . PPACK was added to the
homogenate (Snal concentration 2 µM1
. and the couoined
'nomoeenate and rose were centrifuged in microconcenttator
tubes at 3 .000 x g for 60 min at 4"C. The volume in the
microconcentratnr was brought
10
450 of with a sodium phos-
phate butler containing aprotinin, 410 The rerentata
was centrifuged again for 2 h at 54100' x g at T C. the volume
was a4tostPl to 7 ml with sedum phosphate buffer supple-
mented with aprotiain 1400 klUIml) . and line mixture was
centrifuged avemight 415 .000 x g at 4`C to yield a fin:•.; volume
of approtiinmtety .50 pl . The filters were rinsed wits 20 pl of the
sodium phosphate with aprotinin buffer and the rinses were
combined with the -
etentates
. The combined extract was
stored at -70°C before performance of Western blotting for
quantification of extracted plasminogen
.
Stattstlrs. Results were expressed as mean values . SD.
Mean values were compared by Student t tests . Signtficarce
was defined as p s 005
.
Resells
Depletion of plasminogen in clots . The plasminogen con-
tent in residual clots was determined by Western blot
analysis and expressed as both ng/mg of zlot and the percent
of that in control clots . One hundred percent plasminogen is
equivalent to 64.7 nglmg of plasminogen (53 .4, 76, n
-
2) .
Figure I shows that clot-associated plasminogen declined
after 30 mar, of incubation with sustained . high concentra-
tions of rl-PA. The highc^t concentrations of in-PA resulted
in the greatest diminution of plasminogen in residual clots .
Erects
of supplementation with plasminogen
. To deter-
mine whether the depletion of plasminogen from clots was
secondary to depletion of plasma plasminugun and respon-
sible for the paradoxical diminution of clot lysis with
high concentrations of rt-PA Iplasmlnogcn steal), additional
clots were exposed to the same
concentrations
of rt-PA
(4 .00 ng/mb in plasma supplemented with equal volumes of
solutions of plasminogen 13 pM; n = 4) or buffer . In tubes
without supplemental plasminogen, the percent of clot lysis
that occurred was only 31 .8
t
16,E in - 4) . In contrast. in
tubes with supplemental plasminogen, the percent of iysis
was increased to 73 .9 ± 1000 In = 41
.
Figure 2A shows the
amount of clot-associated plasminogen expressed as a per-
err t of that in control clots incubated without either tt •PA or
supplemental plasminogen
. Conservation of clot-associated
loss
	
taunt rpt..
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Figure
1.
Human clots were formed from whole flood in Chandler
tubes for 60 min ai 37C and incubated for an additional 30 min with
added recombinant tissue-type plasminogen activator It-PA) . Deple-
tion of clot-associated plasminogen was greatest with increasing
concentration oft-PA (n = 2 for each set of conditions),
plasminogen induced wi Ih supp!ementation of the fluid phase
with 3 pM of plasminogen is evident. Figure 2B shows the
potentiation of lysis of clots incubated with rt-PA by supple-
mental plasminogen tp :
0
.051 compared with that of clots
incubated with rt-PA alone
.
Effects of ,shrill degradation products on clot
lysis induced
by rt-PA . To determine whether fibrinogen degradation
products generated by high concentrations of rt-PA could
Figure 2
. Clots were formed in whole blood Chandler tubes with
and witnout supplementation with plasminogen . In tubes that were
supplemented with plasminagen . clot-assecated plasminogen (Alas
a percent of that in control clots was slightly but significantly
incrcat ed fast°risk, p-u 0
.115 : n = 4). Clot lysfs BI was significantly
increased in samples supplemented with nlasminugen compared
with shoes supplemented with recombinant tissue-tripe plasminogen
activator tt-PA) alone lasterish, p < 0 .05 : n = 4) .
Pa. t
u soo 000
2000
4000
8000
1-P6
1-P
.
account for apparent plasminogen steal and paradoxic atten-
uation of clot lysis by competing for binding of plasminogen
activator to fibrin, clots formed in Chandler tithes were
exposed to rt-PA in the presence
or
absence of exogenous
fibrinogen degradation products (50 pg/mq . Preliminary re-
sulls showed that the maximal
concentration
of fibrinogen
degradation products . generated in 90-min incubations with
8,000 ng/nd of rt-PA, was <50 puglml . Fibrinogen degrade-
tion products did not attenuate lysis with any of the concen-
trations of rt-PA used (Fig . 3) . ]n fact, lysis was potentiated
significantly at both 4,000 and 8,000 nglml of rt-PA (p
c
0 .05 ;
n 8), consistent with some potentiation of activation of
plasminogen by the fibrinogen degradation prod -acts them-
selves (16)
.
Effects of depletion of plasminogen induced without rl-PA
on clot-associated plasminogen and subsequent clot lysis with
rt-PA. After formation of whole blood clots in Chandler
tubes for 60 min, some clots were transferred to plasnaiuo-
gee-depleted plasma and incubated for 30 min with tt-PA
(1
.000 ngtml)
. Control clots were placed in normal plasma
containing physiologic concentrations of plasminogen with
the same concentration of rt-PA . The resulting lysis and
residual clot-associated plasminogen were determined grae-
imetrically and by Western biotting.
The concentration of free plasrnin remaining in the fluid
phase after the formation of the clot in the Ist 30 min of
incubation was similar far both sets of clots (0.028 ±
0 .003 CU)ml for those incubated in plasminagen-depleted
plasma compared with 0 .027 ± 0 .003 CU/ml for those
incubated in normal plasma In
m
4]l, indicating similar
contributions of fluid-phase free plasmin in both sets of
conditions . Lysis of clots incubated in the plasminogen-
depleted plasma with 1 .000 nglml rl-PA was attenuated
compared with that of clots incubated in normal plasma
supplemented with ri-PA (p = 0
.05) (Fig. 4A(. -this concen-
ration of ri-PA was chosen to determine whether lower
concentrations of rt-PA can induce plasminogen steal when
fluid- phase plasminogen is depleted by an alternative
method . Clot iysis was coca greater when prefertrcc, trots
were incubated in whole blood supplemented with rt-PA
J 4 CC Vet. 11 . Ne . 5
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Figure 5. Fibrinogen (Icgradetion products
FDA (50 pglmh were
added to some samples with rcomtrinant usue-typo plasminogen
ac ;ivamr It-PA) IIAf0 to 8.1110 nglmll to determine whether the
generation of lbrinagen degradation products by i-PA could he
responsible to, the diminution of clot lysis seen with high concern
tratioms of plasminogen cc :imtors . At high concentrations (4 .WD
and 8,0110 nglmlt of(-PA, lysis was enhanced rather than attenuated
(n = 8)
. Statistical significance (p = 0
.05) of differences between
lysis with and without fibrinogen degradation products is denoted by
asterisks .
(n = 8) than when they were incubated in plasma . Clots
formed in whole blood and exposed to no exogenous rt-PA
contained 26 .5 ± 1 .78 ng of plasminogen per mg of clot in =
2). The concentration of Blot-associated plasminogen was
significantly lower )p < 0
.01) when clots were incubated
subsequently in plasminogen-depleted plasma (9 .:00 08
0.46 nglmg ; n = 6) rather than in normal plasma 117.39 =
0.69; n -= 6) (Fig. 4B) .
Discussion
The present study was performed to explore 10111 recent
hypothesis that plasminugen steal can account for a limita-
Fgure 4
. Preformned clots were
incubated with or without rccom .
biltant tissue-type plasminogen
activator It-PA) 11,000 ng)mll in
plasminogen-depleted or normal
plasma. Clot lysis (A) was virtu-
ally abolished is the plasminogen-
depleted plasma i p =0.05; n = S)
and
slat-associated
plasmntagen
was depleted (p
ti
0 .01 ; n = 6)
compared with that seen in clots
exposed to 111
"
. in normal plasma
(B) . Statistical significance is de-
noted by one lp s 0.05) or two
Ip 10 .011 aft-M.
lion of clot lysis with nonselective plasminogen activators
because of depiction of plasminogen from whole blood in
cioo, Results obtained show that the paiadaxic diminution of
clot iysis seen whit suptapitminaeotuyic . high
concentrations
of rt-PA is associated not only with depletion of plasminogen
fromm the fluid phase- but also with depletion of clot-
associated plasminogen. reflecting an equilibdium between
the two with a consequent reduction of the availability of
clot-associated sshstratc Iplasminogea) for activation .
Effect of depletion of plasminogen on iysis . Confirmation
of a causal connection between depletion of plasminogen
and attenuation of iysis wax obtained in experiments in
which whop He-4 clnrs were incubated in plasminogen-
depleted plasma supplemented with rt-PA .
Clot iysis was
attenuated compared with lysis of clots incubated with rL-PA
in plasmn with physiologic concentrations of plasminogen
despite the presence of similar concentrations of free plas-
min in the fluid phase under both sets of conditions
. These
results indicate that the attenuation of clot iysis is a result of
depletion of dot-associated plasminogen rather than dente .
lion of plasminogen in the fluid phase itself. whether Far not
plasmin is present in the fluid phase .
As was the case with clots incubated with the highest
concentrations of rt-PA
. clot-associated plasminogen was
decreased is clots incubated with lower concentrations of
rt-PA in plasminugen-deficient plasma . In addition. lysis was
attenuated . These observations corroborate the diminution
of plasminogen in the fluid phase as a determinant, regard-
less of how it is induced, of
both depletion of clot-associated
plasminogen and attenuation of clot lys is. The greater induc-
tion of Ivsis of clots incubated in whole blood than of clots
incubated in plasma with physiologic concentrtions of
plasminogen may be attributable to contributions of red
blood cells and platelets to lysis of clots induced by plas-
minogen activators . Cellular elements such as platelets can
facilitate activation of plasminogen by providing a surface on
which plasminogen and rt.mA can bind and inletact (17A) .
Clinical implicalians of plasminemln . Relatively clot-
sdectu-e plasminogen activators were developed on tae
basis of the premise that induction of clot lysis without the
plasminemia associated with nendot-selective drugs would
FORR ET A :-. M99
OL,SMlt)tJEN STEAL
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reduce the risk of bleeding . Surprisingly, however, com-
pared with first-generation agents, these newer agents were
found to induce a more frequent and more rapid recanaliza-
tion of infarct-related arteries (2 .6,19) . These phenomena
may be explained in part by recently characterized plasmin-
mediatec prothtombotic effects of plasminogen activators
(20.21) that can shift the balance herweon dynamic throm-
bonyttc and thrmbotic processes toward thrombosis, with
consequently delayed recanalization and decreased fre-
quency of recanalization with first-generation agents. High
concentrations of plasmin can activate platelets in vitro and
in vivo (22-24) . an effect that may contribute to potentiation
of thrombosis by first-generation agents as well .
As shown in the present study, induction of plasminemia
may axon adverse effects by additional mechanisms . Thus.
marked activation of circulating plasminogen with a corre-
sponding diminution of the concentration of plasminogen
can induce plasminogen steal with consequent attenuation of
clot lysis. Depletion
of plasminogen
is, of course. more
marked with first- than with second-generation plasminogen
activators because of the relative clot selectivity of second-
generation agents
.
Effect of fibrinogen degradation products- The paradoxic
reduction in lysis seen with plasminogen steal in the present
Study is not attributable to high concentrations of fibrinogen
degradation products that could hypothetically compete with
fibrin far binding of tite plasminogen activator. Tied,, addi-
tion of exogenous fibrinogen degradation products did not
diminish lyslo . In fact, the opposite occurred-that is, po-
lenliation of !ysis-an effect that may reflect binding of both
ri-PA and plasminogen to the E-domain
of
fibrinogen degra.
dation products and enhancement of activation of plasmino-
gen (16) . Obviously, plasmin in the fluid phase could con-
tribute to lysis directly if alpha2antiplasmin was already
consumed. Conversely, the depletion of plasminogen ac-
companying generation of plasmin could reduce lysis by
inducing plasminogen steal
. The balance is probably gov-
erned by the extent to which alpha r
aStiplasmin persists in
the fluid phase . Regardless . generation of fibrinogen degra-
dation products does not account for the attenuation of
clot
lysis snail under conditions in wlticn plasminogen steal
occurs .
Conclusions, Our results are consistent with the hypoth-
esis that induction of throacbvly - is with clot-selective agents
facilitates recanalization by avoiding marked plasminemia
and the subsequent attenuation of lysis accompanying plas-
minogen steal,
We thank Barbara Donnelly for expen secretarial assistance in the prepare
.
nor at this manuscript .
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